By Regenerative Medicine China · Published and sources checked · Patient information. Individual treatment and study eligibility require the responsible clinical team’s assessment.
Can someone with KRAS G12D pancreatic cancer find another treatment option in China?
Possibly, but KRAS G12D alone does not identify an available or suitable treatment. A useful review combines the exact diagnosis, current treatment response, previous drugs, molecular report and the criteria of a named study or approved treatment. Confirm a hospital’s written response before changing care or planning travel.
First establish what is happening on current treatment
A search for another option may mean planning ahead, investigating side effects or responding to documented progression. These are different situations. Ask the treating oncologist to state the reason for seeking review and summarise the most recent scan comparison. A report that lists a medicine does not tell a second team whether it is working, tolerable or about to be stopped.
Create a short treatment timeline with start and end dates, best response and reason for each change. Add pathology and the sites of disease. If the available summary does not include earlier chemotherapy or the latest assessment, label that information as missing. Do not fill the gaps with assumptions such as “all standard treatments failed”.
Separate three different treatment questions
For pancreatic ductal adenocarcinoma, an oncology review should consider established systemic treatment as well as research options. NCI describes chemotherapy, targeted approaches and biomarker-selected immunotherapy within pancreatic cancer care; supportive care also belongs in the discussion. A trial search should not displace a useful treatment without a clinical reason. NCI treatment overview.
- KRAS-directed medicines: identify the drug and whether the study concerns G12D specifically or a broader RAS target.
- Engineered T-cell research: establish the exact tumour target and any required HLA type; the label “cell therapy” is insufficient.
- Other trials or established care: ask what remains appropriate given previous treatment, general health and the patient’s goals.
These routes have different evidence, eligibility rules and practical demands. Compare them against the same questions: what is the objective, what evidence supports this use, what could prevent participation and what is the alternative?
Use current regulatory information without assuming local access
On 26 August 2026, the US FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma after at least one systemic therapy, or who are not candidates for multiagent systemic therapy. This US decision does not establish approval, prescribing access or reimbursement in China. FDA announcement.
When a China-based offer names a drug, ask the institution to specify the access route and its documentary basis. A clinical trial, an approved indication and a proposed use outside an approved indication require different explanations. Do not treat an overseas approval announcement as a substitute for that answer.
A molecular match is a starting filter
Check the full molecular report rather than a list of gene names. KRAS G12D is distinct from other KRAS variants, and some engineered T-cell approaches also depend on a particular HLA molecule. Preserve exact spelling when asking about a study. A team should explain which result matches which criterion and what remains unverified.
NCI notes that a biomarker match may suggest a treatment or trial, but does not guarantee benefit or participation. Additional tumour features, earlier treatments and other eligibility requirements still matter. NCI biomarker testing guidance.
Our separate guides address KRAS G12D and HLA-C*08:02, prior daraxonrasib exposure and MSS and PD-L1-negative results. They answer different questions and should not be collapsed into a single “eligible” label.
Two dated examples from China trial records
The following examples were checked on 27 September 2026. They illustrate why a trial needs more than a matching mutation; they are not a patient-specific shortlist or confirmation of a place.
- GFH375 phase III, NCT07262567: the 14 August 2026 update lists a recruiting Beijing site for previously treated KRAS G12D metastatic pancreatic cancer. It excludes previous G12D-directed or pan-RAS/KRAS therapy. Someone already taking a RAS-targeted drug must disclose it before considering this record. Read the GFH375 record.
- LY3962673, MOONRAY-01, NCT06586515: the 24 August 2026 update says recruiting overall, while the four listed mainland China sites, including Shanghai, are not yet recruiting. A global status cannot substitute for a local-site reply. Read the MOONRAY-01 record.
Confirm the current protocol, relevant cohort and local status directly with the institution. Registry entries are dated summaries; a new site status or protocol amendment can change the practical answer.
Ask for a written prescreening outcome before travel
For each serious possibility, record the study identifier or exact treatment, institution, responsible department and date of the response. Ask whether the team is offering records review, a consultation or formal screening. A positive prescreen does not guarantee enrolment, treatment production or a hospital admission date.
Request a list of missing records and a statement about current site availability. Clarify how previous RAS inhibitors are treated in the protocol, whether extra pathology or HLA testing is needed and who will assess travel fitness. Our Shanghai prescreening guide explains how to organise that request without presuming access to a particular hospital.
Keep costs and the alternative plan visible
Ask for separate estimates for consultation, screening, any treatment, hospital care and extended accommodation. Establish what happens if screening fails or a cell product cannot be given. Do not assume a study covers routine medical care or international travel. NCI distinguishes research costs from routine patient-care costs in its US guidance; Chinese site terms must be confirmed separately. Clinical trial cost categories.
Before committing, have a plan for continuing care at home if no suitable opportunity is confirmed. RMC can help organise an enquiry; eligibility and treatment decisions belong to the institution and the patient’s clinical team.
Prepare for your review
- Exact pathology, stage and current scan assessment.
- Complete prior-treatment timeline, including RAS-targeted drugs.
- Full molecular and any relevant HLA reports.
- Named treatment or study, institution and current site response.
- Screening, cost, follow-up and alternative-care questions answered.
Common questions
Does KRAS G12D mean I qualify for TCR-T?
No. The exact T-cell receptor, required HLA type, study criteria, medical assessment and an available site all matter. A mutation match is only one part of screening.
Should I stop a current drug before contacting a hospital in China?
Do not change treatment to make an enquiry. Discuss any proposed change with the prescribing oncologist and the receiving research team; the study’s rules and a safe care plan must be clarified first.
Can RMC guarantee a clinical trial place?
No. RMC can help organise records and questions. Only the responsible study site can confirm current screening possibilities and final eligibility.
Sources and evidence boundaries
- ClinicalTrials.gov: GFH375, NCT07262567
- ClinicalTrials.gov: MOONRAY-01, NCT06586515
- NCI: pancreatic cancer treatment
- FDA: daraxonrasib approval, 26 August 2026
- NCI: biomarker testing for cancer treatment
- NCI: who pays for clinical trials
Registry status and local access can change. A public listing, molecular match or source citation is not a hospital partnership, a reserved place or confirmation of eligibility. Published research and overseas approvals should be interpreted in their stated setting. This guide does not present an RMC patient outcome.